Literature DB >> 2274789

Genetic mechanisms of tumor suppression by the human p53 gene.

P L Chen1, Y M Chen, R Bookstein, W H Lee.   

Abstract

Mutations of the gene encoding p53, a 53-kilodalton cellular protein, are found frequently in human tumor cells, suggesting a crucial role for this gene in human oncogenesis. To model the stepwise mutation or loss of both p53 alleles during tumorigenesis, a human osteosarcoma cell line, Saos-2, was used that completely lacked endogenous p53. Single copies of exogenous p53 genes were then introduced by infecting cells with recombinant retroviruses containing either point-mutated or wild-type versions of the p53 cDNA sequence. Expression of wild-type p53 suppressed the neoplastic phenotype of Saos-2 cells, whereas expression of mutated p53 conferred a limited growth advantage to cells in the absence of wild-type p53. Wild-type p53 was phenotypically dominant to mutated p53 in a two-allele configuration. These results suggest that, as with the retinoblastoma gene, mutation of both alleles of the p53 gene is essential for its role in oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2274789     DOI: 10.1126/science.2274789

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  126 in total

1.  A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells.

Authors:  D A Haber; H T Timmers; J Pelletier; P A Sharp; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

2.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

Review 3.  Cancer risks from germline p53 mutations.

Authors:  T Frebourg; S H Friend
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 4.  Nuclear protein phosphorylation and growth control.

Authors:  D W Meek; A J Street
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

5.  Repression of the basal c-fos promoter by wild-type p53.

Authors:  N Kley; R Y Chung; S Fay; J P Loeffler; B R Seizinger
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

6.  A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs.

Authors:  G P Zambetti; D Olson; M Labow; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

7.  Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses.

Authors:  D Ronen; Y Teitz; N Goldfinger; V Rotter
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

8.  Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy.

Authors:  A Asai; Y Miyagi; A Sugiyama; M Gamanuma; S H Hong; S Takamoto; K Nomura; M Matsutani; K Takakura; Y Kuchino
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

Authors:  B Roy; J Beamon; E Balint; D Reisman
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines.

Authors:  J Yeargin; J Cheng; A L Yu; R Gjerset; M Bogart; M Haas
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.